Anemia
News
NK-cell therapy in resistant MDS, AML
Results of a phase 1/2 trial suggest treatment with haploidentical natural killer (NK) cells can be effective against relapsed/refractory...
News
Young kids with SCA not receiving recommended prophylaxis
Many young children with sickle cell anemia (SCA) may not be taking the recommended antibiotics to prevent invasive pneumococcal disease (IPD),...
News
Azacitidine now available in China
Azacitidine for injection (Vidaza®) is now available in China. The nucleoside metabolic inhibitor was approved in China to treat patients with...
News
FDA expands approved use of ferumoxytol injection
The US Food and Drug Administration (FDA) has expanded the approved indication for ferumoxytol injection (Feraheme®). The drug is now approved to...
From the Journals
Children with sickle cell anemia fall short on antibiotic adherence
Identify barriers to prophylactic antibiotics for sickle cell patients at the time of health care interventions.
CME
Iron deficiency anemia: Disease heterogeneity and the rapid evolution of traditional diagnosis and treatment paradigms
News
FDA places T-cell therapy on clinical hold
The US Food and Drug Administration (FDA) has placed BPX-501, a T-cell therapy being evaluated in patients who undergo haploidentical...
From the Journals
Sotatercept promising for treatment of anemia in MDS
The phase 2 trial included patients who did not respond to erythropoiesis-stimulating agents.
News
Predicting response to AZA in MDS, CMML
Researchers have developed a technique that may help predict whether patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic...
News
Drug receives breakthrough designation for SCD
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to voxelotor (previously GBT440) for the treatment of...
Conference Coverage
Caplacizumab improves outcomes in aTTP
ATLANTA—Caplacizumab can improve outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP), according to research presented at...